BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/21/2020 1:38:19 AM | Browse: 758 | Download: 1056
 |
Received |
|
2020-03-14 00:46 |
|
Peer-Review Started |
|
2020-03-14 00:47 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2020-04-29 18:57 |
|
Revised |
|
2020-05-11 20:09 |
|
Second Decision |
|
2020-07-16 10:49 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2020-07-19 21:55 |
|
Articles in Press |
|
2020-07-19 21:55 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2020-07-30 13:44 |
|
Publish the Manuscript Online |
|
2020-08-21 01:38 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Review |
| Article Title |
Combination drug regimens for metastatic clear cell renal cell carcinoma
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Viraj V Khetani, Daniella E Portal, Mansi R Shah, Tina Mayer and Eric A Singer |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Eric A Singer, FACS, MA, MD, Associate Professor, Urology and Urologic Oncology, Rutgers Cancer Institute of New Jersey, 195 Little Albany Street, New Brunswick, NJ 08903, United States. eric.singer@rutgers.edu |
| Key Words |
Renal cell carcinoma; Immunotherapy; Targeted therapy; Vascular endothelial growth factor; Programmed-death receptor 1; Programmed-death receptor ligand-1 |
| Core Tip |
The treatment of metastatic clear cell renal cell carcinoma (ccRCC) remains a challenge given the broad spectrum of disease presentations and outcomes, variety of treatment options without clear optimal sequencing, and the low rate of complete response to systemic monotherapy. The core of this work reviews the current status of systemic combination drug options in the treatment of metastatic ccRCC, encompassing the novel combinations of tyrosine kinase inhibitors and immune checkpoint inhibitors, with a focus on rationale for use, efficacy, and side effect profiles. We also discuss the role of biomarkers in the development of future therapeutic options. |
| Publish Date |
2020-08-21 01:38 |
| Citation |
Khetani VV, Portal DE, Shah MR, Mayer T, Singer EA. Combination drug regimens for metastatic clear cell renal cell carcinoma. World J Clin Oncol 2020; 11(8): 541-562 |
| URL |
https://www.wjgnet.com/2218-4333/full/v11/i8/541.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v11.i8.541 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
